Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM340FH)

Drug Name
cinnamic acid Drug Info
Synonyms
CINNAMIC ACID; TRANS-CINNAMIC ACID; 140-10-3; 621-82-9; (E)-Cinnamic acid; trans-3-Phenylacrylic acid; 3-Phenylacrylic acid; Phenylacrylic acid; Zimtsaeure; (2E)-3-phenylprop-2-enoic acid; 3-phenylprop-2-enoic acid; E-Cinnamic Acid; 3-Phenylpropenoic acid; (E)-3-phenylprop-2-enoic acid; trans-beta-Carboxystyrene; Benzenepropenoic acid; trans-Cinnamate; (E)-3-Phenyl-2-propenoic acid; (E)-cinnamate; Benzeneacrylic acid; trans-3-Phenyl-2-propenoic acid; Cinnamylic acid; Cinnamic acid, (E)-; t-Cinnamic acid; (2E)-3-Phenyl-2-propenoic
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
444539
ChEBI ID
CHEBI:35697
CAS Number
CAS 140-10-3
TTD Drug ID
DM340FH
INTEDE Drug ID
DR2499

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DOT
Drug Status:
Investigative Drug(s)
Approved Drug(s)
Clinical Trial Drug(s)
Discontinued Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Phosphomevalonate kinase (PMVK)
Drug Name Drug ID Indication ICD 11 Highest Status REF
(R)-5-diphosphomevalonate DMOESL1 Discovery agent N.A. Investigative [7]
isoferulic acid DMN23KT Discovery agent N.A. Investigative [3]
3-hydroxy-3-methyl-6-phosphohexanoic acid DM3YO72 Discovery agent N.A. Investigative [8]
Drug(s) Targeting Nicotinic acid receptor (HCAR2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Vitamin B3 DMQVRZH Chronic renal failure GB61.Z Approved [9]
ARI-3037MO DM9LNXS Cardiovascular disease BA00-BE2Z Phase 2 [10]
SCH-900271 DMBJY1Z Ischemic stroke 8B11.5Z Phase 2 [11]
GSK-256073 DMMAIY2 Hyperlipidaemia 5C80 Phase 2 [12]
MK-1903 DMVJB09 Arteriosclerosis BD40 Phase 2 [13]
MK-0354 DMWFTRJ N. A. N. A. Phase 2 [14]
NIA-114 DM3ADQW Plaque psoriasis EA90.0 Clinical trial [15]
INCB19602 DMRHZBD Type-2 diabetes 5A11 Discontinued in Phase 2 [16]
5-Benzyl-1H-pyrazole-3-carboxylic acid DMJVGUZ Discovery agent N.A. Investigative [17]
Sazetidine-A DM68JI5 Major depressive disorder 6A70.3 Investigative [11]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Hydroxycarboxylic acid receptor 2 (HCAR2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Tretinoin DM49DUI Acne vulgaris ED80 Approved [18]
Leflunomide DMR8ONJ Arthritis FA20 Approved [19]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [20]
Folic Acid DMEMBJC Colorectal carcinoma Approved [21]
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [22]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [23]
Urethane DM7NSI0 N. A. N. A. Phase 4 [24]
Benzo(a)pyrene DMN7J43 N. A. N. A. Phase 1 [25]
Milchsaure DM462BT Pruritus EC90 Investigative [26]
[3H]cAMP DMZRQU7 Discovery agent N.A. Investigative [27]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Steroid 17-alpha-hydroxylase/17,20 lyase (CYP17A1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Etretinate DM2CZFA Keratosis ED56 Approved [28]
FADROZOLE DM3C5GZ Breast cancer 2C60-2C65 Approved [29]
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [4]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [30]
Prasterone DM67VKL Chronic obstructive pulmonary disease CA22 Approved [31]
Testosterone DM7HUNW Hot flushes GA30 Approved [31]
Pyruvic acid DM7Q41G Malnutrition 5B50-5B71 Approved [32]
Topiramate DM82Z30 Alcohol dependence 6C40.2 Approved [33]
Lamotrigine DM8SXYG Bipolar disorder 6A60 Approved [33]
ABIRATERONE DM8V75C Prostate cancer 2C82.0 Approved [34]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Cytochrome P450 2E1 (CYP2E1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Fomepizole DM6VOWQ Athylene glycol or methanol poisoning NE61 Approved [35]
Ademetionine DMYQDBO Hepatic fibrosis DB93.0 Approved [36]
Theophylline DMRJFN9 Bronchitis CA20 Approved [37]
Rifampicin DM5DSFZ Non-insulin dependent diabetes 5A11 Approved [38]
Ethanol DMDRQZU Chronic pain MG30 Approved [39]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [40]
Phenobarbital DMXZOCG Cluster headache 8A81.0 Approved [41]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [42]
Didanosine DMI2QPE Human immunodeficiency virus infection 1C62 Approved [37]
Thioridazine DM35M8J Schizophrenia 6A20 Approved [43]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Cytochrome P450 3A4 (CYP3A4)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Eplerenone DMF0NQR Heart failure BD10-BD13 Approved [44]
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [45]
Isotretinoin DM4QTBN Acne vulgaris ED80 Approved [46]
Voriconazole DMAOL2S Aspergillosis 1F20 Approved [47]
Proguanil DMBL79I Malaria 1F40-1F45 Approved [48]
Ivermectin DMDBX5F Intestinal strongyloidiasis due to nematode parasite 1F6B Approved [48]
Loratadine DMF3AN7 Allergy 4A80-4A85 Approved [49]
Nelfinavir mesylate DMFX6G8 N. A. N. A. Approved [50]
Capsaicin DMGMF6V Back pain ME84.Z Approved [51]
Axitinib DMGVH6N Renal cell carcinoma 2C90 Approved [52]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Cytochrome P450 2C8 (CYP2C8)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Simvastatin DM30SGU Arteriosclerosis BD40 Approved [53]
Cyclophosphamide DM4O2Z7 Advanced cancer 2A00-2F9Z Approved [54]
Lovastatin DM9OZWQ Arteriosclerosis BD40 Approved [53]
Ifosfamide DMCT3I8 Adult central nervous system germ cell tumor Approved [54]
Sulfinpyrazone DMEV954 Gout FA25 Approved [55]
Loratadine DMF3AN7 Allergy 4A80-4A85 Approved [53]
Zafirlukast DMHNQOG Asthma CA23 Approved [53]
Ethinyl Estradiol DMODJ40 Acne vulgaris ED80 Approved [53]
Sorafenib DMS8IFC Adenocarcinoma 2D40 Approved [56]
Dabrafenib DMX6OE3 Melanoma 2C30 Approved [57]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Cytochrome P450 2D6 (CYP2D6)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [58]
Paliperidone DM7NPJS Psychotic disorder 6A20-6A25 Approved [59]
Dopamine DMPGUCF Acromegaly 5A60.0 Approved [60]
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [61]
Oxatomide DM1F42Z Hay fever CA08.00 Approved [62]
Cinacalcet DMCX0K3 Hyperparathyroidism 5A51 Approved [63]
Capsaicin DMGMF6V Back pain ME84.Z Approved [64]
Pentamidine DMHZJCG African trypanosomiasis 1F51 Approved [48]
Quinidine DMLPICK N. A. N. A. Approved [65]
Buprenorphine DMPRI8G Opioid dependence 6C43.2Z Approved [66]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Cytochrome P450 2A6 (CYP2A6)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Tegafur DM31ZQM Solid tumour/cancer 2A00-2F9Z Approved [67]
Methoxsalen DME8FZ9 Cutaneous T-cell lymphoma 2B01 Approved [68]
Fluorouracil DMUM7HZ Adenocarcinoma 2D40 Approved [69]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [70]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [40]
Progesterone DMUY35B Amenorrhea GA20.0 Approved [71]
Ifosfamide DMCT3I8 Adult central nervous system germ cell tumor Approved [72]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [73]
Letrozole DMH07Y3 Estrogen-receptor positive breast cancer Approved [74]
Nicotine DMWX5CO Lung cancer 2C25.0 Approved [75]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Cytochrome P450 2C9 (CYP2C9)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [45]
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [76]
Dapsone DM4LT8A Acne vulgaris ED80 Approved [48]
Voriconazole DMAOL2S Aspergillosis 1F20 Approved [47]
Capsaicin DMGMF6V Back pain ME84.Z Approved [64]
Zafirlukast DMHNQOG Asthma CA23 Approved [77]
Niclosamide DMJAGXQ Cestodes infection 1F70-1F76 Approved [48]
Eicosapentaenoic acid/docosa-hexaenoic acid DMMUCG4 Hypertriglyceridemia 5C80.1 Approved [78]
Fluconazole DMOWZ6B Cryptococcal meningitis Approved [47]
Quinine DMSWYF5 Malaria 1F40-1F45 Approved [48]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By 3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 2 (HSD3B2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [4]
Topiramate DM82Z30 Alcohol dependence 6C40.2 Approved [33]
Lamotrigine DM8SXYG Bipolar disorder 6A60 Approved [33]
Lindane DMB8CNL Infestations of lice and scabies 1G00.Z Approved [79]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [80]
Metyrapone DMI7FVQ Cushing disease 5A70 Approved [81]
Rosiglitazone DMILWZR Chronic kidney disease GB61 Approved [4]
Niclosamide DMJAGXQ Cestodes infection 1F70-1F76 Approved [82]
Pioglitazone DMKJ485 Amyotrophic lateral sclerosis 8B60.0 Approved [83]
Levetiracetam DMTGDN8 Epilepsy 8A60-8A68 Approved [80]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Cytochrome P450 2C19 (CYP2C19)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [45]
Thioridazine DM35M8J Schizophrenia 6A20 Approved [43]
Voriconazole DMAOL2S Aspergillosis 1F20 Approved [47]
Chloramphenicol DMFXEWT Bacterial infection 1A00-1C4Z Approved [84]
Capsaicin DMGMF6V Back pain ME84.Z Approved [64]
Pentamidine DMHZJCG African trypanosomiasis 1F51 Approved [48]
Stiripentol DMMSDOY Dravet syndrome 8A61.11 Approved [85]
Quinine DMSWYF5 Malaria 1F40-1F45 Approved [48]
Desipramine DMT2FDC Attention deficit hyperactivity disorder 6A05.Z Approved [43]
Amitriptyline DMK7F9S Depression 6A70-6A7Z Approved [37]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Nitric oxide synthase 3 (NOS3)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [86]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [87]
Bosentan DMIOGBU Pulmonary arterial hypertension BB01.0 Approved [37]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [88]
Methotrexate DM2TEOL Anterior urethra cancer Approved [89]
Simvastatin DM30SGU Arteriosclerosis BD40 Approved [90]
Quercetin DM3NC4M Obesity 5B81 Approved [6]
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [91]
Fructose DM43AN2 Vomiting MD90 Approved [92]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [93]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Nicotinic acid receptor (HCAR2) TTWNV8U HCAR2_HUMAN Agonist [2]
Phosphomevalonate kinase (PMVK) TTXMI0C PMVK_HUMAN Inhibitor [3]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 2 (HSD3B2) OT02MSKN 3BHS2_HUMAN Gene/Protein Processing [4]
Cytochrome P450 2A6 (CYP2A6) OT52TWG3 CP2A6_HUMAN Gene/Protein Processing [4]
Cytochrome P450 2C19 (CYP2C19) OTFMJYYE CP2CJ_HUMAN Gene/Protein Processing [4]
Cytochrome P450 2C8 (CYP2C8) OTHCWT42 CP2C8_HUMAN Gene/Protein Processing [4]
Cytochrome P450 2C9 (CYP2C9) OTGLBN29 CP2C9_HUMAN Gene/Protein Processing [4]
Cytochrome P450 2D6 (CYP2D6) OTZJC802 CP2D6_HUMAN Gene/Protein Processing [4]
Cytochrome P450 2E1 (CYP2E1) OTHQ17JG CP2E1_HUMAN Gene/Protein Processing [4]
Cytochrome P450 3A4 (CYP3A4) OTQGYY83 CP3A4_HUMAN Gene/Protein Processing [4]
Hydroxycarboxylic acid receptor 2 (HCAR2) OTZM930L HCAR2_HUMAN Protein Interaction/Cellular Processes [5]
Nitric oxide synthase 3 (NOS3) OTLDT7NR NOS3_HUMAN Gene/Protein Processing [6]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3203).
2 Phenolic acids suppress adipocyte lipolysis via activation of the nicotinic acid receptor GPR109A (HM74a/PUMA-G). J Lipid Res. 2009 May;50(5):908-14.
3 Inhibition of rat liver mevalonate pyrophosphate decarboxylase and mevalonate phosphate kinase by phenyl and phenolic compounds. Biochem J. 1979 Jul 1;181(1):143-51.
4 Cinnamic acid based thiazolidinediones inhibit human P450c17 and 3beta-hydroxysteroid dehydrogenase and improve insulin sensitivity independent of PPARgamma agonist activity. J Mol Endocrinol. 2004 Apr;32(2):425-36.
5 Structure-activity relationships of trans-substituted-propenoic acid derivatives on the nicotinic acid receptor HCA2 (GPR109A). Bioorg Med Chem Lett. 2011 May 1;21(9):2736-9. doi: 10.1016/j.bmcl.2010.11.091. Epub 2010 Nov 25.
6 A blend of polyphenolic compounds explains the stimulatory effect of red wine on human endothelial NO synthase. Nitric Oxide. 2005 Mar;12(2):97-104.
7 Functional evaluation of conserved basic residues in human phosphomevalonate kinase. Biochemistry. 2007 Oct 23;46(42):11780-8.
8 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 641).
9 Hakozaki T, Minwalla L, Zhuang J, Chhoa M, Matsubara A, Miyamoto K, Greatens A, Hillebrand GG, Bissett DL, Boissy RE: The effect of niacinamide on reducing cutaneous pigmentation and suppression of melanosome transfer. Br J Dermatol. 2002 Jul;147(1):20-31.
10 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
11 Discovery of SCH 900271, a Potent Nicotinic Acid Receptor Agonist for the Treatment of Dyslipidemia. ACS Med Chem Lett. 2011 Nov 24;3(1):63-8.
12 GSK256073, a selective agonist of G-protein coupled receptor 109A (GPR109A) reduces serum glucose in subjects with type 2 diabetes mellitus. Diabetes Obes Metab. 2013 Nov;15(11):1013-21.
13 Niacin lipid efficacy is independent of both the niacin receptor GPR109A and free fatty acid suppression. Sci Transl Med. 2012 Aug 22;4(148):148ra115.
14 GPR109a agonists. Part 2: pyrazole-acids as agonists of the human orphan G-protein coupled receptor GPR109a. Bioorg Med Chem Lett. 2010 Aug 1;20(15):4472-4.
15 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
16 DOI: 10.1038/scibx.2010.313
17 Pyrazole derivatives as partial agonists for the nicotinic acid receptor. J Med Chem. 2003 Aug 28;46(18):3945-51.
18 Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Cells. 2020 Nov 5;9(11):2423. doi: 10.3390/cells9112423.
19 Endoplasmic reticulum stress and MAPK signaling pathway activation underlie leflunomide-induced toxicity in HepG2 Cells. Toxicology. 2017 Dec 1;392:11-21.
20 Integrative "-Omics" analysis in primary human hepatocytes unravels persistent mechanisms of cyclosporine A-induced cholestasis. Chem Res Toxicol. 2016 Dec 19;29(12):2164-2174.
21 Folic acid supplementation dysregulates gene expression in lymphoblastoid cells--implications in nutrition. Biochem Biophys Res Commun. 2011 Sep 9;412(4):688-92. doi: 10.1016/j.bbrc.2011.08.027. Epub 2011 Aug 16.
22 Activation of AIFM2 enhances apoptosis of human lung cancer cells undergoing toxicological stress. Toxicol Lett. 2016 Sep 6;258:227-236.
23 17-Estradiol Activates HSF1 via MAPK Signaling in ER-Positive Breast Cancer Cells. Cancers (Basel). 2019 Oct 11;11(10):1533. doi: 10.3390/cancers11101533.
24 Ethyl carbamate induces cell death through its effects on multiple metabolic pathways. Chem Biol Interact. 2017 Nov 1;277:21-32.
25 Air pollution and DNA methylation alterations in lung cancer: A systematic and comparative study. Oncotarget. 2017 Jan 3;8(1):1369-1391. doi: 10.18632/oncotarget.13622.
26 Transcriptional profiling of lactic acid treated reconstructed human epidermis reveals pathways underlying stinging and itch. Toxicol In Vitro. 2019 Jun;57:164-173.
27 Modulation of HDL metabolism by the niacin receptor GPR109A in mouse hepatocytes. Biochem Pharmacol. 2010 Nov 1;80(9):1450-7. doi: 10.1016/j.bcp.2010.07.023. Epub 2010 Jul 22.
28 Retinoids and retinol differentially regulate steroid biosynthesis in ovarian theca cells isolated from normal cycling women and women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2005 Aug;90(8):4858-65. doi: 10.1210/jc.2005-0330. Epub 2005 May 24.
29 Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitors of aldosterone synthase. J Med Chem. 2005 Mar 10;48(5):1563-75.
30 Use of organ culture to study the human fetal testis development: effect of retinoic acid. J Clin Endocrinol Metab. 2006 Jul;91(7):2696-703.
31 Inhibition of CYP17 expression by adrenal androgens and transforming growth factor beta in adrenocortical cells. Acta Biochim Pol. 2004;51(4):907-17.
32 Phosphorylation of CtBP1 by cAMP-dependent protein kinase modulates induction of CYP17 by stimulating partnering of CtBP1 and 2. J Biol Chem. 2008 Mar 14;283(11):6925-34. doi: 10.1074/jbc.M708432200. Epub 2008 Jan 9.
33 Effects of anticonvulsants on human p450c17 (17alpha-hydroxylase/17,20 lyase) and 3beta-hydroxysteroid dehydrogenase type 2. Epilepsia. 2005 Mar;46(3):444-8.
34 A fission yeast-based test system for the determination of IC50 values of anti-prostate tumor drugs acting on CYP21. J Enzyme Inhib Med Chem. 2006 Oct;21(5):547-56.
35 Chemical inhibitors of cytochrome P450 isoforms in human liver microsomes: a re-evaluation of P450 isoform selectivity. Eur J Drug Metab Pharmacokinet. 2011 Mar;36(1):1-16.
36 Inhibition of CYP2E1 catalytic activity in vitro by S-adenosyl-L-methionine. Biochem Pharmacol. 2005 Apr 1;69(7):1081-93.
37 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
38 Characterization of primary human hepatocytes, HepG2 cells, and HepaRG cells at the mRNA level and CYP activity in response to inducers and their predictivity for the detection of human hepatotoxins. Cell Biol Toxicol. 2012 Apr;28(2):69-87.
39 An in vitro model of human acute ethanol exposure that incorporates CXCR3- and CXCR4-dependent recruitment of immune cells. Toxicol Sci. 2013 Mar;132(1):131-41.
40 Multiple microRNAs function as self-protective modules in acetaminophen-induced hepatotoxicity in humans. Arch Toxicol. 2018 Feb;92(2):845-858.
41 Proteomic analysis of hepatic effects of phenobarbital in mice with humanized liver. Arch Toxicol. 2022 Oct;96(10):2739-2754. doi: 10.1007/s00204-022-03338-7. Epub 2022 Jul 26.
42 Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
43 Inhibition of cytochrome P450 enzymes participating in p-nitrophenol hydroxylation by drugs known as CYP2E1 inhibitors. Chem Biol Interact. 2004 Apr 15;147(3):331-40.
44 The relative role of CYP3A4 and CYP3A5 in eplerenone metabolism. Toxicol Lett. 2019 Oct 15;315:9-13.
45 Characterization of the structural determinants required for potent mechanism-based inhibition of human cytochrome P450 1A1 by cannabidiol. Chem Biol Interact. 2014 May 25;215:62-8.
46 Retinoids activate the RXR/SXR-mediated pathway and induce the endogenous CYP3A4 activity in Huh7 human hepatoma cells. Toxicol Sci. 2006 Jul;92(1):51-60.
47 The novel azole R126638 is a selective inhibitor of ergosterol synthesis in Candida albicans, Trichophyton spp., and Microsporum canis. Antimicrob Agents Chemother. 2004 Sep;48(9):3272-8.
48 Application of higher throughput screening (HTS) inhibition assays to evaluate the interaction of antiparasitic drugs with cytochrome P450s. Drug Metab Dispos. 2001 Jan;29(1):30-5.
49 Cetirizine and loratadine-based antihistamines with 5-lipoxygenase inhibitory activity. Bioorg Med Chem Lett. 2004 Nov 15;14(22):5591-4.
50 Mechanism-based inactivation of CYP3A by HIV protease inhibitors. J Pharmacol Exp Ther. 2005 Feb;312(2):583-91.
51 Studies of the toxicological potential of capsinoids, XIII: inhibitory effects of capsaicin and capsinoids on cytochrome P450 3A4 in human liver microsomes. Int J Toxicol. 2010 Mar;29(2 Suppl):22S-6S.
52 Investigation of the effects of axitinib on the pharmacokinetics of loperamide and its main metabolite N-demethylated loperamide in rats by UPLC-MS/MS. Chem Biol Interact. 2019 Sep 1;310:108744. doi: 10.1016/j.cbi.2019.108744. Epub 2019 Jul 9.
53 Examination of 209 drugs for inhibition of cytochrome P450 2C8. J Clin Pharmacol. 2005 Jan;45(1):68-78.
54 Identification of the polymorphically expressed CYP2C19 and the wild-type CYP2C9-ILE359 allele as low-Km catalysts of cyclophosphamide and ifosfamide activation. Pharmacogenetics. 1997 Jun;7(3):211-21.
55 Essential requirements for substrate binding affinity and selectivity toward human CYP2 family enzymes. Arch Biochem Biophys. 2003 Jan 1;409(1):32-44.
56 Differential inhibition of human CYP2C8 and molecular docking interactions elicited by sorafenib and its major N-oxide metabolite. Chem Biol Interact. 2021 Apr 1;338:109401. doi: 10.1016/j.cbi.2021.109401. Epub 2021 Feb 5.
57 Dabrafenib inhibits ABCG2 and cytochrome P450 isoenzymes; potential implications for combination anticancer therapy. Toxicol Appl Pharmacol. 2022 Jan 1;434:115797. doi: 10.1016/j.taap.2021.115797. Epub 2021 Nov 13.
58 Human recombinant cytochrome P450 enzymes display distinct hydrogen peroxide generating activities during substrate independent NADPH oxidase reactions. Toxicol Sci. 2014 Oct;141(2):344-52. doi: 10.1093/toxsci/kfu133. Epub 2014 Jul 24.
59 Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone. Psychopharmacology (Berl). 1999 Dec;147(3):300-5. doi: 10.1007/s002130051171.
60 Effect of penicillin-based antibiotics, amoxicillin, ampicillin, and piperacillin, on drug-metabolizing activities of human hepatic cytochromes P450. J Toxicol Sci. 2016 Feb;41(1):143-6.
61 Cannabidiol, a major phytocannabinoid, as a potent atypical inhibitor for CYP2D6. Drug Metab Dispos. 2011 Nov;39(11):2049-56. doi: 10.1124/dmd.111.041384. Epub 2011 Aug 5.
62 Identification of human P450 isoforms involved in the metabolism of the antiallergic drug, oxatomide, and its kinetic parameters and inhibition constants. Biol Pharm Bull. 2005 Feb;28(2):328-34.
63 Pharmacokinetics of desipramine HCl when administered with cinacalcet HCl. Eur J Clin Pharmacol. 2007 Feb;63(2):159-63.
64 Effects of capsaicin and dihydrocapsaicin on human and rat liver microsomal CYP450 enzyme activities in vitro and in vivo. J Asian Nat Prod Res. 2012;14(4):382-95.
65 Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test. Clin Pharmacol Ther. 2001 Oct;70(4):327-35.
66 Interaction of buprenorphine and its metabolite norbuprenorphine with cytochromes p450 in vitro. Drug Metab Dispos. 2003 Jun;31(6):768-72.
67 Cyp2a6 is a principal enzyme involved in hydroxylation of 1,7-dimethylxanthine, a main caffeine metabolite, in humans. Drug Metab Dispos. 2005 Sep;33(9):1361-6. doi: 10.1124/dmd.105.004796. Epub 2005 Jun 24.
68 Mimicking gene defects to treat drug dependence. Ann N Y Acad Sci. 2000;909:233-46. doi: 10.1111/j.1749-6632.2000.tb06685.x.
69 Expression of CYP2A6 in tumor cells augments cellular sensitivity to tegafur. Jpn J Cancer Res. 2001 May;92(5):524-8. doi: 10.1111/j.1349-7006.2001.tb01125.x.
70 CYP1A1/1B1 and CYP2A6/2A13 activity is conserved in cultures of differentiated primary human tracheobronchial epithelial cells. Toxicol In Vitro. 2011 Jun;25(4):922-9.
71 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
72 Measurement of 4-hydroxylation of ifosfamide in human liver microsomes using the estimation of free and protein-bound acrolein and codetermination of keto- and carboxyifosfamide. J Cancer Res Clin Oncol. 2002 Jul;128(7):385-92.
73 Integrated 'omics analysis reveals new drug-induced mitochondrial perturbations in human hepatocytes. Toxicol Lett. 2018 Jun 1;289:1-13.
74 Deactivation of anti-cancer drug letrozole to a carbinol metabolite by polymorphic cytochrome P450 2A6 in human liver microsomes. Xenobiotica. 2009 Nov;39(11):795-802. doi: 10.3109/00498250903171395.
75 A novel single nucleotide polymorphism altering stability and activity of CYP2a6. Biochem Biophys Res Commun. 2001 Mar 2;281(3):810-4. doi: 10.1006/bbrc.2001.4422.
76 Comparative effects of thiazolidinediones on in vitro P450 enzyme induction and inhibition. Drug Metab Dispos. 2003 Apr;31(4):439-46.
77 Potential of pranlukast and zafirlukast in the inhibition of human liver cytochrome P450 enzymes. Xenobiotica. 2004 May;34(5):429-38.
78 The inhibitory effect of polyunsaturated fatty acids on human CYP enzymes. Life Sci. 2006 Nov 25;79(26):2432-40.
79 Steroidogenic gene expression in H295R cells and the human adrenal gland: adrenotoxic effects of lindane in vitro. J Appl Toxicol. 2006 Nov-Dec;26(6):484-92.
80 Differential effects of antiepileptic drugs on steroidogenesis in a human in vitro cell model. Acta Neurol Scand Suppl. 2009;(189):14-21.
81 The H295R system for evaluation of endocrine-disrupting effects. Ecotoxicol Environ Saf. 2006 Nov;65(3):293-305.
82 Mitochondrial Uncoupling Induces Epigenome Remodeling and Promotes Differentiation in Neuroblastoma. Cancer Res. 2023 Jan 18;83(2):181-194. doi: 10.1158/0008-5472.CAN-22-1029.
83 Pioglitazone inhibits androgen production in NCI-H295R cells by regulating gene expression of CYP17 and HSD3B2. Mol Pharmacol. 2007 Mar;71(3):787-98.
84 Cytochrome P450 inhibition potential of new psychoactive substances of the tryptamine class. Toxicol Lett. 2016 Jan 22;241:82-94.
85 Stiripentol. Expert Opin Investig Drugs. 2005 Jul;14(7):905-11.
86 Protective effects of S-carvedilol on doxorubicin-induced damages to human umbilical vein endothelial cells and rats. J Appl Toxicol. 2019 Aug;39(8):1233-1244. doi: 10.1002/jat.3809. Epub 2019 May 7.
87 Oxidative stress in kidney transplant patients with calcineurin inhibitor-induced hypertension: effect of ramipril. J Cardiovasc Pharmacol. 2002 Oct;40(4):625-31.
88 Hydrogen peroxide decreases endothelial nitric oxide synthase promoter activity through the inhibition of Sp1 activity. DNA Cell Biol. 2009 Mar;28(3):119-29.
89 Global molecular effects of tocilizumab therapy in rheumatoid arthritis synovium. Arthritis Rheumatol. 2014 Jan;66(1):15-23.
90 Simvastatin inhibits cigarette smoking-induced emphysema and pulmonary hypertension in rat lungs. Am J Respir Crit Care Med. 2005 Oct 15;172(8):987-93. doi: 10.1164/rccm.200501-041OC. Epub 2005 Jul 7.
91 The thiazolidinedione drug troglitazone up-regulates nitric oxide synthase expression in vascular endothelial cells. J Diabetes Complications. 2006 Sep-Oct;20(5):336-42.
92 Fructose induces the inflammatory molecule ICAM-1 in endothelial cells. J Am Soc Nephrol. 2008 Sep;19(9):1712-20.
93 Upregulation of nitric oxide production in vascular endothelial cells by all-trans retinoic acid through the phosphoinositide 3-kinase/Akt pathway. Circulation. 2005 Aug 2;112(5):727-36. doi: 10.1161/CIRCULATIONAHA.104.500959. Epub 2005 Jul 25.